QCM
UTHR icon

Qsemble Capital Management’s United Therapeutics UTHR Stock Holding History

Qsemble Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-671
Closed -$364K – 496
2026
Q2 		$364K Sell
671
-380
-36% -$214K 0.05% 315
2026
Q1 		$623K Sell
1,051
-330
-24% -$164K 0.05% 327
2025
Q4 		$673K Buy
+1,381
New +$643K 0.06% 334
2025
Q3 		– Sell
-1,563
Closed -$449K – 612
2025
Q2 		$449K Buy
+1,563
New +$467K 0.04% 332

Other funds holding UTHR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Qsemble Capital Management's UTHR Position: Q3 2026 in Review

Qsemble Capital Management sold out of United Therapeutics (UTHR) in Q3 2026, closing a stake of 671 shares — an estimated $364K sold.

Qsemble Capital Management first reported a position in UTHR in Q2 2025 and held it in 4 quarters. The position peaked at $673K in Q4 2025. 673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Qsemble Capital Management reported no remaining United Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 671 United Therapeutics shares in Q3 2026, an estimated $364K.
  • Qsemble Capital Management first reported a position in United Therapeutics in Q2 2025 and held it in 4 quarters.
  • Qsemble Capital Management's United Therapeutics position peaked at $673K in Q4 2025.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Qsemble Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.